IP Library Granted Patent US 11,274,123
Granted Patent B2
US 11,274,123 · App. 16/245,860 · Granted Mar 15, 2022

1,2,4-oxadiazole compounds as inhibitors of CD47 signalling

Inventors: Pottayil Govindan Nair Sasikumar (Bangalore, IN); Muralidhara Ramachandra (Bangalore, IN); Seetharamaiah Setty Sudarshan Naremaddepalli (Bangalore, IN); Chennakrishnareddy Gundala (Bangalore, IN)
Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
C07K5/0215A61P9/10A61P25/28A61P35/02C07D271/06C07D413/04C07D413/12C07D413/14A61K38/00A61P31/04A61P31/10A61P31/16A61P31/18A61P31/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,274,123
App. No.
16/245,860
Granted
Mar 15, 2022
Kind
B2
Abstract

The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.

Claims (46)

1. A compound of formula (IA):

or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof; wherein,

R a is hydrogen or acyl;

R 1 represents hydrogen, —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —CH 2 COOH, —(CH 2 ) 3 NHC(═NH)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 CONH 2 , —CH(CH 3 )—CH 2 —CH 3 , —CH 2 -aryl, or —CH 2 — heteroaryl; wherein the said aryl and heteroaryl are unsubstituted; or R a and R 1 , together with the atoms to which they are attached form pyrrolidine ring optionally substituted with oxo group; and

R 2 represents —(CH 2 ) 3 NHC(═NH)NH 2 .

2. The compound of claim 1 , wherein R 1 represents hydrogen, —CH 2 —COOH, —CH 2 —CONH 2 , —CH(CH 3 )—CH 2 —CH 3 , —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —(CH 2 ) 3 NHC(═NH)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 -phenyl, —CH 2 -indolyl or —CH 2 -imidazolyl.

3. The compound of claim 1 , wherein,

R a is hydrogen; and R 1 represents hydrogen, —CH 2 —COOH, —CH 2 —CONH 2 , —CH(CH 3 )—CH 2 —CH 3 , —(CH 2 ) 2 CONH 2 , —(CH 2 ) 2 COOH, —(CH 2 ) 3 NHC(═NH)NH 2 , —(CH 2 ) 4 NH 2 , —CH 2 -phenyl, —CH 2 -indolyl or —CH 2 -imidazolyl.

4. A compound that is:

Com-

pound

Structure

 1

 2

3

4

5

6

7

8

9

10

11

12

13

14

15

or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.

5. A pharmaceutical composition comprising a compound of formula (IA) according to claim 1 , and a pharmaceutically acceptable carrier.

6. A compound of the formula:

or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.

7. A pharmaceutical composition comprising a compound according to claim 6 , and a pharmaceutically acceptable carrier.

8. The compound of claim 6 , which is of the formula:

9. The compound of claim 6 , which is of the formula:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 6 , which is of the formula:

or an amide thereof.

11. The compound of claim 6 , which is of the formula:

or an ester thereof.

12. The compound of claim 6 , which is of the formula:

or a stereoisomer thereof.

13. A pharmaceutical composition comprising a compound according to claim 8 , and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a compound according to claim 9 , and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising a compound according to claim 10 , and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a compound according to claim 11 , and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising a compound according to claim 12 , and a pharmaceutically acceptable carrier.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 064952 FRAME 0575. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Oct 24, 2023
From: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
To: AURIGENE ONCOLOGY LIMITED
Reel/Frame 065332/0962 →
CHANGE OF NAME Recorded Sep 19, 2023
From: AURIGENE DISCOVERY TECHNOLOGIES PRIVATE LIMITED
To: AURIGENE ONCOLOGY LIMITED
Reel/Frame 064952/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2020
From: SASIKUMAR, POTTAYIL GOVINDAN NAIR; RAMACHANDRA, MURALIDHARA; NAREMADDEPALLI, SEETHARAMAIHA SETTY SUDARSHAN; CHENNAKRISHNAREDDY, GUNDALA
To: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
Reel/Frame 052135/0471 →
Priority Claims (1)
IN 201841001438 · Jan 12, 2018 · national
Continuity (1)
Related Publication 20190218252A1 · Jul 18, 2019
Cited By (1)
US 12,565,515